Psyence Biomedical (PBM) Debt Ratio (2023 - 2024)
Psyence Biomedical's (PBM) quarterly Debt Ratio came in at 0.56 in Q3 2024, down 100.0% year-on-year from 126795955777.02 in Q4 2023, and down 57.3% quarter-over-quarter from 1.3 in Q1 2024.
Psyence Biomedical (PBM) Debt Ratio (2023 - 2024) Analysis & Trends
Psyence Biomedical's Debt Ratio history runs 2 years deep, the most recent figure standing at 0.56 for Q3 2024.
- On a quarterly basis, Debt Ratio fell 100.0% year-over-year to 0.56 in Q3 2024; TTM through Sep 2024 was 0.56, a 100.0% decrease from a year earlier, with the FY2024 full-year figure at 1.3, changed N/A from the prior year.
- Debt Ratio fell to 0.56 in Q3 2024 per PBM's latest filing, from 1.3 in the prior quarter.
- Across five years, Debt Ratio topped out at 126788591968.2 in Q3 2023 and bottomed at 0.56 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 1.41 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.11 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.05 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Psyence Biomedical | 1.56 Mn | 1.56 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 0.56 |
| Mar 31, 2024 | 1.30 |
| Sep 30, 2023 | 126.79 Bn |